SCHEMBL4803385

SCHEMBL4803385

CCCC(CCCNCc1ccccc1)Oc1cccc2sccc12

nearest known ligand 0.37

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SCN8A Q9UQD0 1/20 0.37
MAOA P21397 1/20 0.37
CHRM2 P08172 1/20 0.36
F9 P00740 1/20 0.36
F10 P00742 1/20 0.36
PLAU P00749 1/20 0.36
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
SIGMAR1 Q99720 3/20 0.35
KDM4E B2RXH2 1/20 0.34
HTR1A P08908 1/20 0.34
NMT2 O60551 1/20 0.33
NMT1 P30419 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
DRD2 P14416 1/20 0.33
DRD4 P21917 1/20 0.33
DRD3 P35462 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4805496 0.96 SCN8A (0.37) SCN8AMAOACHRM2F9F10
SCHEMBL4804702 0.84 MEN1 (0.38) SCN8AMAOACHRM2F9F10
SCHEMBL4804483 0.79 SLC6A2 (0.44) KMT2AHTR1ADRD2DRD3
Hydrochloric Acid SCHEMBL4798564 0.78 SLC6A2 (0.43) KMT2AHTR1ADRD2DRD3
SCHEMBL4804877 0.78 SLC6A2 (0.42) KMT2AHTR1ADRD2DRD3
SCHEMBL4797438 0.77 HTR1D (0.40) MAOASIGMAR1
Hydrochloric Acid SCHEMBL4801165 0.77 SLC6A2 (0.42) KMT2AHTR1ADRD2DRD3
SCHEMBL4802484 0.76 HTR1D (0.39) MAOASIGMAR1
Hydrochloric Acid SCHEMBL6301709 0.70 HTR2A (0.32)
SCHEMBL22495434 0.68 MPO (0.53) MAOACHRM2MEN1KMT2ASIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7417064-B2 3-aryloxy/thio-3-substituted propanamines and their use in inhibiting serotonin and norepinephrine reuptake ELI LILLY AND COMPANY (US) 2008-08-26 US disclosed
US-20060014779-A1 3-Aryloxy/thio-3-substituted propanamines and their use in inhibiting serotonin and norephinephrine reuptake ELI LILLY AND COMPANY (US) 2006-01-19 US disclosed
EP-1587782-A1 3-ARYLOXY/THIO-3-SUBSTITUTED PROPANAMINES AND THEIR USE IN INHIBITING SEROTONIN AND NOREPINEPHRINE REUPTAKE Eli Lilly and Company (US) 2005-10-26 EP disclosed
WO-2004043904-A1 3-ARYLOXY/THIO-3-SUBSTITUTED PROPANAMINES AND THEIR USE IN INHIBITING SEROTONIN AND NOREPHINEPHRINE REUPTAKE ELI LILLY AND COMPANY (US) 2004-05-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014779-A1 3-Aryloxy/thio-3-substituted propanamines and their use in inhibiting serotonin and norephinephrine reuptake ADRB3, HTR3C, CHRNB3 SCN8A 862/4885MAOA 133/4885CHRM2 58/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.